Table 1 Demographic and clinical characteristics of the study population
Demographic and clinical characteristics | n (%) or median (IQR) |
|---|---|
Males | 565 (74.5%) |
Age (years) | 33 (27–41) |
Year of ART initiation | |
2009 | 240 (31.7%) |
2013–2015 | 518 (68.3%) |
Follow-up time (weeks) | 144 (108–276) |
Baseline viral load (copies/ml) | |
< 100 000 | 499 (65.8%) |
≥ 100 000 and < 500 000 | 211 (27.8%) |
≥ 500 000 | 48 (6.3%) |
Mode of transmission | |
Homosexual | 290 (38.3%) |
Heterosexual | 378 (49.9%) |
Bisexual | 21 (2.8%) |
Othersa | 15 (2.0%) |
Unknown | 54 (7.1%) |
Baseline CD4 level (cells/mm3) | |
< 100 | 96 (12.7%) |
≥ 100 and < 200 | 143 (18.9%) |
≥ 200 and < 350 | 338 (44.6%) |
≥ 350 | 181 (23.9%) |
Subtype | |
AE | 224 (29.6%) |
B/C/BC | 111 (14.6%) |
Others | 17 (2.2%) |
Unknown | 406 (53.6%) |
Regimen | |
TDF + 3TC + EFV | 517 (68.2%) |
3TC + AZT + NVP | 78 (10.3%) |
3TC + AZT + EFV | 14 (1.8%) |
3TC + TDF + NVP | 7 (0.9%) |
Other 2NRTIs + NNRTI | 142 (18.7%) |
Serum HBsAg status | |
Positive | 89 (12.1%) |
Negative | 645 (87.9%) |
Serum HCV-Ab status | |
Positive | 29 (4.0%) |
Negative | 699 (96.0%) |
Resistance | |
Low, intermediate and high | 16 (4.5%) |
Susceptible and potential low | 337 (95.5%) |